The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

Aalto University scientists have created a laser-based treatment that uses gentle heat to stop the progression of dry macular ...

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

The Retina Group of New York is offering SYFOVRE™, a revolutionary treatment option for age-related dry macular degeneration (AMD) with geographic atrophy. We are thrilled to offer SYFOVRE to our ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

A new approach pioneered by Aalto University scientists uses controlled warmth to trigger self-repair within retinal cells ...

Retina Group of New York introduces IZERVAY™, a Safe and Effective Treatment for Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA). We are thrilled to offer IZERVAY, a new drug ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular degeneration, ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...